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The Cytochrome P450 family serves as the forefront for
xenobiotic metabolism in the human body. An understanding
of the mechanism behind this enzyme family is a necessity
for later research in the areas of pharmaceuticals and
biochemistry. It has been observed by previous researchers
that the transient species compound I, a highly reactive π-
cation radical intermediate, is able to be viewed with
P450cam and other heme containing proteins with subjection
to various oxidant compounds such as m-CPBA or peracetic
acid. In this study Cytochrome P450BM3 and its’ heme
domain, P450BMH, has been reacted with various oxidant
compounds to show evidence of this compound I intermediate
by diode array spectrophotometry and electron paramagnetic
resonance spectroscopy.
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CHAPTER I
INTRODUCTION
General Description of Cytochrome P450
Considered by most to be the “first line of defense”
for xenobiotic metabolism, the Cytochrome P450 family uses
its ability to oxidize reactants to form products that are
more water soluble and thereby more easily released by the
human body. A desire to understand the mechanism behind
Cytochrome P450 enzymes has grown exponentially over the
last three decades as a result. Originally thought to only
be housed in the liver and small intestines of mammals,
research has discovered P450 enzymes in the brain1, kidneys2
and skin3 of mammals and in some plants4, bacteria5 and
fungi6 as well. As of today more than 50 genes have been
mapped that code for P450 enzymes in humans. There are two
general classes of P450 enzymes with which one can perform
research to further the understanding of this family of
enzymes. These classes may be described as bacterial
P450’s and microsomal P450’s, both of which have unique
characteristics that aid in the understanding of P450
2
enzymes as a whole. Bacterial P450’s tend to be cytosolic
in nature and their study has aided in the understanding of
reaction mechanisms due to their greater ease of
purification. Consequently, applications in the field of
biotechnology involving P450 enzymes tend to make use of
this class in general. Microsomal P450 research aims at
understaning human xenobiotic metabolism, which is a major
component of the field of pharmacology. Other areas
impacted by P450 research include toxicology and general
health and nutrition. Any science that in some way
addresses the impact of foreign chemicals on human health
must include some element of Cytochrome P450 biochemistry
in their research efforts.
P450 nomenclature
In 1986 there were close to 30 genes reported which
coded for P450 enzymes in humans and close to 40 genes in
rats. This made the need for a systematic way of naming
and categorizing different P450s essential. The
nomenclature of a particular P450 enzyme is easy to break
down and is done as follows.7 Most often Cytochrome P450 is
simply denoted as CYP for simplicity. The first number
that comes after this notation corresponds to the P450
3
family to which the enzyme belongs. A letter following
this number represents the enzymes’ subfamily, which is
used when two or more subfamilies are known to exist within
the main family. A final number denotes the individual
gene that codes for that particular P450.7 As with all
rules made in the scientific world there are exceptions.
This holds true in P450 nomenclature as well. The
nomenclature scheme described holds true for a majority of
human P450 genes, however, if there appears to be no
subfamily or second functional gene in a particular P450
family there is no need to assign a subfamily or individual
gene when naming the enzyme. An example of this would be
CYP21, which is the only functional gene in the CYP21
family, so the gene and enzyme can be simply referred to as
CYP21. In addition to the systematic naming of genes, many
P450 enzymes have common names based on their discovery in
a new organism, or function. A few examples of this would
include CYPBM3(CYP102) and CYPCam(CYP101) which are found
in Bacillus Megaterium and Pseudamonas Putida respectively.
Finally, when attempting to determine to which main family
a P450 gene belongs the “40% rule” is implemented. The
gene that codes for a newly discovered P450 enzyme is
aligned with several genes that code for different P450
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families to test for similarities between the two. If
there is a 40% similarity or more between the two genes
then the new P450 gene is a member of that family, however,
if there is less than a 40% similarity between the new P450
gene and any other previously discovered P450 family then
that gene is the first in a new P450 family.
Structure of Cytochrome P450
1. Overall Structure
What we know as of now about the overall structure of
Cytochrome P450 can be mainly attributed to the crystal
structures of P450cam and P450BM3, which were published in
1987.8,9,10 Since then studies have shown that the overall
fold of the P450 enzyme is extremely conserved, where no
non-P450 enzyme shares a similar tertiary structure.11,12
Most Cytochrome P450 enzymes contain a heme domain only,
which is responsible for the biochemistry that takes place
in the enzyme. However, several members of the P450 family
have been identified that are functional fusion proteins in
which the heme domain is connected to an auxiliary
reductase enzyme that feeds needed electrons to the heme
domain which are contributed by the biological electron
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donor, NADPH or NADH. Within the P450 family the general
rule is the further within the structure, or closer to the
heme, the more conserved the enzyme structure between
isoforms become. These secondary structures of the P450
enzyme include the I, L and G helices. The L and G helices
are mainly responsible for the formation of the unique fold
in the P450 tertiary structure. Also the L helix, along
with the I helix, is in direct contact with the heme active
site of P450. Just before the L helix lies the β bulge
section, which is responsible for holding the cystiene
residue in place that directly bonds to the iron center of
the heme. One characteristic, or fingerprint, of each P450
enzyme is the B’ helix whose orientation and component
residues directly contribute to what type of substrates are
allowed into the active site.
6
Figure 1: Overall tertiary structure of P450 enzymes.13
7
Figure 2: P450cam illustrating key conserved helical
structures.13
2. Active Site Structure
As stated earlier, a cysteine residue housed by the β
bulge, is responsible for holding the iron center of the
heme active site in place. This heme active site is a
porphyrin ring system that contains a redox active iron ion
and is identical to the cofactor found in hemoglobin,
myoglobin and many other biologically important redox
enzymes. Several angstroms from the porphyrin ring system
lie key residues that determine what particular substrate
8
will be allowed entry to the active site of the enzyme.
Also these amino acid residues mediate electron transfer
within the enzyme; several of these residues are shown in
figure 3.
Figure 3: Active site structure of Cytochrome P450-BM3.14
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Figure 4: Catalytic cycle of Cytochrome P450.
The metabolic process of Cytochrome P450 takes place
at its heme iron active site where a cyclic reduction-
oxidation occurs converting substrate into an oxidized
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product, often via the addition of a hydroxyl group to the
reactant structure. Cytochrome P450 cannot do this process
without the use of two key ingredients: molecular oxygen
and the electron donating compound NADPH in the case of
type II P450’s. Electrons donated from NADPH are sent from
the flavin domain of Cytochrome P450 reductace to the heme
domain to aid in the reduction of the iron center of the
heme active site. Molecular oxygen is then bound to the
iron center and a second electron from NADPH is added to
reduce the iron center to the 3+ state. With the addition
of hydrogen ions from the surrounding environment a water
molecule is formed from one oxygen atom from molecular
oxygen while the other oxygen atom forms a double bond with
the iron producing a high valent state of iron which is now
highly reactive and able to perform hydroxylation chemistry
on the substrate. The time period to perform one cycle of
this chemistry is remarkably short, and the initial steps
in the cycle are relatively slow. This presents somewhat
of a challenge when attempting to observe iron
intermediates beyond the ferrous complex in the reaction
cycle.
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Transient Intermediates in the P450 Reaction Cycle
There has been a great deal of interest in the
characterization and identification of reactive
intermediates in the P450 catalytic cycle for some time
now. Cryogenic research has allowed for the study of
multiple P450 isoforms15,16,17 which, as a result of this low
temperature studies, has allowed for the observation of
catalytic species beyond the second electron transfer in
the proposed catalytic cycle of P450.18,19 These studies
have, in turn, raised the question of what precise
catalytic species is involved in the hydroxylation or if
there may be more than one species responsible for the
biochemistry occurring in P450 enzymes. Stated previously,
it is quite difficult to study reactive intermediates in
the P450 cycle because the rate of the reactions after
formation of the oxyferryl intermediate are very fast when
compared to the slower rates of formation of intermediates
before this in the catalytic cycle. A way to “by pass”
this slow step is to present a molecule to the enzyme that
can donate an oxygen atom directly to the iron and
generate, in a single step, the “ultimate oxidant” in
12
catalysis. Identifying the “ultimate oxidant” is the key
component of my research.
Research Goals
In an attempt to directly detect potential reactive
intermediates in the P450 cycle, a technique known as
stopped-flow spectrophotometry will be used. It has been
discovered through research from various peroxidase enzymes
and heme containing enzymes such as horseradish
peroxidase20, cytochrome c periodase21, and horse heart
metmyoglobin22 that an unstable species known as compound I
is formed on the heme active site by the introduction of
oxidants such as meta-chloro perbenzoic acid, or m-CPBA.
Compound I consists of an oxyferryl, porphyrin π-cation
radical intermediate that forms on the porphyrin ring
system of these proteins/enzymes. The result is a highly
reactive intermediate, which is responsible for initiating
oxidative reactions through electron transfer. As a result
of this π-cation radical being so unstable, it may react
with a neighboring residue, in most cases a tryptophan or
tyrosine, resulting in an oxidized amino acid radical at or
near the active site. Through diode array
13
spectrophotometry and electron paramagnetic resonance
spectroscopy (EPR) at the appropriate pH it is possible to
observe these transient intermediates. Combining these
methods, an attempt to determine the exsistance of compound
I and related intermediates in Cytochrome P450-BM3 has been
implemented in this research endeavor. Oxidants such as
meta-chloroperbenzoic acid (m-CPBA) along with
iodosobenzene, sodium m-periodate and peracetic acid were
used in this study to show the ability to form high valent
heme intermediates in P450-BM3. The oxidants m-CPBA and
peracetic acid have been used in related kinetic studies
involving P450Cam and evidence for the occurrence of high
valent, transient intermediates in this enzyme have been
reported.23,24 Schunemann et. al. showed in their studies of
P450cam that EPR radical signals produced by reacting
peracetic acid with P450Cam were removed by the mutation of
tyrosine residues located near the active site.23 Stopped
flow and EPR analysis of P450Cam by Spolitak and Ballou at
pH levels greater than 7.0 have also shown formation of
compound I with the use of m-CPBA and peracetic acid as
oxidants.24 In the current study, the oxidants are
introduced to wild type BM3 as well as various site
directed mutants of this enzyme in an attempt to determine
14
which key residue(s) is/are responsible for the removal of
the π-cation radical from the porphyrin ring system of the
heme in the active site. Since the oxygen atom donor
bypasses the electron transfer step, the flavin domain is
theoretically unnecessary for the experiments. Therefore,
further mutants of BM3 comprising solely of the heme domain
are also used containing complementary residue mutations.
Diode array spectrophotometry coupled with stopped-flow
mixing has been used to observe the transient intermediates
that form, while EPR analysis is used to show the existence
of residue radicals that form from the removal of the
radical cation from the porphryin.
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CHAPTER II
MATERIALS AND METHODS
Site-Directed Mutagenesis of P450BM3/BMH and Mutagenesis
Screening
To produce the appropriate mutant enzymes of
Cytochrome P450BM3/BMH primers were constructed containing
the appropriate codon sequence that coded for the desired
amino acid residue mutation. For the full length protein,
P450BM3, two single site mutations were made. Phe87 was
mutated to a glycine in order to allow bulkier oxidant
compounds used in this study to enter the active site.
Trp96 was mutated to a histidine in an attempt to determine
if this residue was responsible for removal of the cation
radical from the porphyrin ring after formation of compound
I. For the heme domain, P450BMH, a single mutation of
Phe87 to glycine and a double mutation of Phe87 to glycine
and Trp96 to histidine were made. Wild type plasmids were
muatated by use of polymerase chain reaction (PCR). One
microliter of plasmid was added to 1µL of reverse and
forward primer, 12.5µL of phusion polymerase master mix
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solution containing deoxyribo-nucleotides and 9.5µL of
deionized water to give a final reaction volume of 25µL.
Phusion polymerase was used for mutagenesis reactions
because of its’ proofreading ability during replication.
Samples were then set to run in a PCR thermal cycler for 30
cycles with a denaturing temperature of 95°C for one minute,
an annealing temperature of 62°C for one minute and a
replication temperature of 72°C for five minutes. To ensure
that the desired mutation was obtained in this new plasmid
a screening test was implemented. A similar solution was
prepared for this test containing 1µL of mutated plasmid,
1µL of positive screening primer, 1µL of reverse primer,
12.5µL of taq polymerase master mix containing deoxyribo-
nucleotides and 9.5µL of deionized water. A duplicate
sample was also prepared containing 1µL of negative
screening primer containing the unmutated sequence at the
3’ end. Taq polymerase was used in this reaction since no
proofreading of the sequencing was required. Samples were
then reacted in the PCR thermal cycler for 30 cycles under
similar conditions with the replication portion of the
cycle reduced to one minute. Once this reaction was
18
completed 2µL of loading dye was added to each sample and
they were then loaded onto a 3% agarose gel suspended in
10% TAE buffer. The gel was allowed to run for one hour at
120V. The gel was then suspended in deionized water
containing 50µL of ethidium bromide for 10 minutes to allow
viewing of bands under UV light.
Production of P450-BM3/BMH and Mutants
To properly grow and express Cytochrome P450-BM3 the
plasmid that allowed for over expression of this enzyme had
to be placed inside an E. Coli strain capable of producing
the T7 RNA polymerase, in this case the strain of E. Coli
BL-21 DE3. Transformation of this expression vector was
done by introduction of 1µL of plasmid to approximately
100µL of competent E. Coli cells while on ice. Samples were
left on ice for 10 minutes and then heat shocked at 42°
Celsius for 1 minute. Samples were then placed on ice for
an additional 2 minutes, 900µL of LB media was added to
allow for reproduction of E. Coli and this was placed in a
37°C incubator for approximately 1 hour. After incubation
was completed 100µL of sample was applied to an agar plate
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with ampicillin resistance and left overnight at 37°C. A
single colony that grew on the agar plate was removed and
introduced to approximately 30mL of Terrific Broth (TB)
media and placed in a 37°C incubator overnight to grow.
Several liters of TB media were prepared for the
introduction of the starter culture by the combination of
12.0g of tryptone, 24.0g of yeast extract, and 4.0mL of
glycerol per one liter of solution. The media was then
autoclaved at 140°C for 35 minutes and allowed to cool.
After the media had reached room temperature 100.0mL of
phosphate buffer at pH 7.4, which was also autoclaved, and
100mg of ampicillin were added to the TB media to prevent
unwanted growth of contaminants in the media.
Approximately 1.0mL of starter culture was then added to
the TB media and growth was allowed to occur for 24-48
hours at room temperature while shaking at approximately
180rpm. Once optimal growth had been reached, 150mg of
IPTG was added to the media to induce the expression of
BM3/BMH enzyme. Expression was then allowed to continue at
room temperature for 24-48 hours at room temperature while
shaking at approximately 80rpm.
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Testing of Expression Levels of P450-BM3/BMH
To test for optimal expression of BM3/BMH
approximately 3.0-5.0mL of TB media containing the E. Coli
cells was centrifuged and the pellet re-suspended in half
volume of equilibration buffer, which comprised of 15%
glycerol by volume, 50mM potassium phosphate buffer at pH
7.4 and 0.1mM EDTA. Sodium dithionite was then added to the
sample to reduce the heme iron to the ferrous state. The
sample was divided into two cuvettes and a baseline
spectrum was recorded using a Cary UV-Vis
Spectrophotometer. One of the two cuvettes was then
removed and carbon monoxide was bubbled through the sample
for approximately 30 seconds. Spectra were recorded every
30 seconds to observe any increase in absorbance at 450nm,
the λmax corresponding to a reduced CO heme complex of
Cytochrome P450.
Purification of P450-BM3 and Mutants
Cultures containing the P450-BM3 and mutant samples
were first centrifuged at 10,000rpm for 20 minutes using a
JA-10 rotor for the Beckman J Series Centrifuge. Pelleted
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samples were then homogenized in equilibration buffer and
the cell walls lysed using lysozyme while mixing for one
hour. Samples were then placed on ice and sonicated at
high frequency for one minute to break down the cell
membrane, which released all cytosolic material from the
cells. Finally, samples were centrifuged again at
18,000rpm for one hour using a JA-20 rotor and the
supernatant that contained the unpurified BM3, was prepared
for liquid chromatography purification.
A DEAE cation exchange column was equilibrated using
3-4 bed volumes of equilibration buffer as defined
previously. Raw enzyme samples were then diluted 3:1 in
equilibration buffer and loaded onto the column. Samples
were then eluted and collected with equilibration buffer
containing 0.2M NaCl. This sample was again diluted 3:1 in
equilibration buffer and loaded on a Q-Sepharose cation
exchange column, also equilibrated using 3-4 bed volumes of
equilibration buffer. Purified enzyme samples were eluted
using a 0.1M-0.30M step gradient of potassium phosphate
buffer at pH 7.4 in 15% glycerol by volume. After
purification a spectrum in the 400-500nm region of each
sample was taken to ensure contaminants were properly
removed. Purification was ensured by a rise in absorbance
22
at 418nm with no other changes in absorbance in that region
of the spectrum.
Alternative Purification Method
In an attempt to purify P450-BMH and mutants an
alternative method of liquid chromatography was used.
Buffers used in this purification process are as follows:
buffer A, 30mM potassium phosphate at pH 7.4, 2mM
dithiothreitol (DTT), 0.1M EDTA; buffer B, 100mM potassium
phosphate at pH 7.0, 1mM DTT, 0.1M EDTA. Cell pellets were
homogenized in buffer A and were then lysed and sonicated
as done previously. Supernatant samples were then diluted
3:1 in buffer A and loaded onto a Q-Sepharose cation
exchange column previously equilibrated in buffer A.
Samples were eluted by passing 100mL of buffer A containing
0.2M KCl and then concentrated to a volume of 5mL. This
sample was then loaded onto a Sephacryl S-200 size
exclusion column equilibrated in buffer B. Remaining
contaminants were separated from the enzyme sample in this
final step and a similar spectrum was taken of the sample
to test for purity, stated previously. A solution of 50%
glycerol was then added to the sample for cold storage
purposes.
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Diode Array Spectrophotometry
Purified P450-BM3/BMH samples were combined with
oxidant solutions and then examined using a High Tech SF-18
double mixing Stopped Flow system with diode array
detection. Oxidant and enzyme samples were prepared prior
to injection by the addition of 500µL of potassium phosphate
buffer at a specified pH, to give a final buffer
concentration 250mM. A zero point spectrum was first
recorded by combining the prepared enzyme sample against a
blank, 250mM potassium phosphate solution. A spectrum was
recorded for one second and used as a means of comparison
for later addition with oxidant solutions. All
experiments, including the zero point spectrum, were
preformed at a constant temperature of 15°C. Oxidant
solutions were prepared at varying, optimal concentrations
as follows: m-CPBA, 125µM; iodosobenzene, 125µM; sodium m-
periodate, 5mM; peracetic acid, 5mM. In an attempt to
observe compound E-S formation, enzyme and oxidant
solutions were prepared at pH 6.8 while to observe compound
I formation solutions were prepared at a pH of 7.4.
Spectra were recorded in triplicate for 1 second, 10 second
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and 50 second reaction times at pH 6.8 to observe the
spectral shift from 418nm to 406nm. Spectra were recorded
from 1 second to 4 seconds to observe compound I formation
at 370nm.
Electron Paramagnetic Resonance (EPR) Spectroscopy
In order to observe a clear radical signal, a higher
concentration of enzyme sample was prepared at
approximately 100µM. Enzyme and oxidant solutions were
prepared in 100mM phosphate buffer at pH 7.4. Oxidant
concentrations varied from 125µM to 400µM. After
preparation of initial samples were completed they were
combined in a 4mm clear fused quartz EPR tube and allowed
to react for approximately 10 seconds before freeze
quenching with liquid nitrogen. Spectra were then recorded
on a Bruker Instruments EMX 6/1 EPR spectrometer at a
microwave power of 50.4µW and a frequency of 9.48GHz. The
temperature was held constant at 10K while recording
spectras by using an Oxford Instruments ESR 900 cryostat.
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CHAPTER III
RESULTS AND DISCUSSION
Plasmid Screening
Using polymerase chain reaction and agarose gel
electrophoresis a positive screen was observed for the
double mutation of Cytochrome P450BMH-F87G:W96H. It should
be noted that this double mutated plasmid was obtained by a
single mutation of the Trp96 codon sequence on a previously
mutated Phe87 plasmid that screened positive for the
mutation. Positive screening primers for both mutations
annealed to the plasmid at 65°C. After suspension of the
agarose gel in an ethidium bromide solution bands were
observed under UV light in the positive mutation lane for
each residue mutation while no band was observed in either
negative mutation lane. This screening ensures that the
properly mutated plasmid is being used throughout this
study.
26
Figure 6: Agarose gel illustrating a positive screen for
both F87G and W96H mutations. Lane 3 positive shows
positive screening for F87G while Lane 5 positive shows
positive screening for W96H.
27
P450 Expression Levels
CO reduced spectra of both F87G and F87G:W96H mutants
of P450BMH revealed a significant drop in expression levels
compared to that of P450BM3. Samples (5mL) of each
mutation were centrifuged and resuspended in half volume of
equilibration buffer for each spectrum. A maximum
absorbance difference of ~.01-.03 over a 5 minute time
course was observed for the BMH-F87G mutation while a
maximum absorbance change of .008-.02 was observed for the
BMH-F87G:W96H mutation which corresponded to the expression
levels of each enzyme in culture. A possible reason for
this lowered expression level could be the resulting
instability of the heme active site by removal of the
tryptophan residue. Hydrogen bonding is known to occur
between this residue and the porphyrin ring in order to
anchor the heme active site in place. Mutation of this
residue alters this bonding scheme. Other possibilities
for a lowered expression level in these heme domain
mutations are also possible.
28
Figure 7: CO reduced spectrum of P450BMH-F87G:W96H.
Spectrum shown is for maximum absorbance obtained over a 5
minute time course.
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Figure 8: CO reduced spectrum of P450BMH-F87G. Spectrum
shown is for maximum absorbance obtained over a 5 minute
time course
30
Diode Array Spectrophotometry
Within milliseconds of the addition of peracetic acid
to Cytochrome P450BM3-W96H at pH 7.4 a shoulder was
observed in the enzyme spectra at 370nm which corresponded
to the formation a π cation radical intermediate on the
porphyrin ring of the heme active site, or compound I.
This trend was also observed with reaction of P450BM3-F87G
with m-CPBA as the oxidant at pH 7.4. This shoulder
rapidly decayed in P450BM3-F87G at pH 6.8 to produce a
strong Soret peak at 406nm which corresponded to the
removal of this cation radical from the porphyrin ring to a
neighboring tryptophan residue, or compound E-S (also
referred to as compound II). This spectral shift to 406nm
gradually came back to its’ original position at 418nm with
moderate bleaching at an optimal oxidant concentration.
Other spectral changes at 575nm and 625nm were evidence of
the formation of the transient compound E-S intermediate
where the oxidant compound has bound to the heme active
site. A spectral change was observed within the first few
milliseconds in this region with a decrease in absorbance
at 575nm with a coincidental increase in absorbance at
625nm.
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A spectral shift to 406nm at pH 6.8 was observed with
all oxidants used in this trial when reacted with P450BM3-
F87G, however, the timeline to observe this shift was
significantly longer with sodium m-periodate at optimal
oxidant concentration. An additional feature was also
observed in the reaction with sodium m-periodate. A rapid
increase in absorbance below 350nm was seen, which may
reflect the formation of a tyrosine dimer between Tyr278
and Tyr 429. These residues are approximately 3.8Ǻ from
one another, which supports the formation of a dimmer
complex. The dimer complex has a maximum absorbance of
~340nm which is observed in the spectra of P450BM3-F87G
within milliseconds of addition of sodium m-periodate. A
proposed reaction mechanism for the formation of this dimer
complex is illustrated in Scheme I and II. The other
oxidants produced a spectral shift to 406nm within a time
frame of 1-10s while sodium m-periodate took up to 30s.
Reaction of Cytochome P450BMH-F87G with m-CPBA
generated a spectrum nearly identical to that of P450BM3-
F87G with a spectral shift to 406nm at pH 6.8 followed by a
shift back to 418nm with moderate bleaching at an optimal
oxidant concentration. Other oxidants reacted in a similar
manner as with P450BM3-F87G, however, an identical spectra
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could not be produced with the oxidant iodosobenzene. The
probable cause for this could be degradation of oxidant
stock as a result of its photosensitivity. An increase in
absorbance at 300nm with reaction of sodium m-periodate
with BMH-F87G showing the presence of a tyrosine dimer
complex as before with BM3-F87G. While the BMH-F87G:W96H
mutant was successfully expressed, analysis of this enzyme
when reacted with any oxidant used in this study could not
be performed. Low expression levels of this double
mutation along with instability of this enzyme during the
purification process as a result of the mutation did not
allow for the analysis. An overall scheme of the formation
and decay of these transient intermediates is illustrated
in Scheme III.
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Figure 9: UV-Vis spectrum of P450BM3-F87G reacted with m-
CPBA at pH 7.4. Enzyme concentration ~500µM, oxidant
concentration 125µM, buffer concentration 250mM. Reaction
temperature held constant at 15°C.
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Figure 10: UV-Vis spectrum of BM3-W96H reacted with
peracetic acid at pH 7.4. Enzyme concentration ~750µM,
oxidant concentration 5mM, buffer concentration 250mM. Time
frame of reaction from t = 0s (red) to t = 2s, reaction
temperature held constant at 15°C.
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Figure 11: UV-Vis spectrum of m-CPBA reacted with BM3-F87G
at pH 6.8. Enlarged region of P450BM3-F87G spectra
illustrating formation of compound E-S intermediate. Enzyme
concentration ~700µM, oxidant concentration 125µM, buffer
concentration 250mM; time frame from 0s(red) to 1s,
temperature held constant at 15°C.
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Figure 12: UV-Vis spectum of BM3-F87G reacted with
iodosobenzene at pH 6.8. Enlarged region of P450BM3-F87G
spectrum illustrating formation of compound E-S
intermediate. Enzyme concentration ~700µM, oxidant
concentration 125µM, buffer concentration 250mM Time frame
from 0s(red) to 10s, reaction temperature held constant at
15°C.
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Figure 13: UV-Vis spectrum of BM3-F87G reacted with sodium
m-periodate at pH 6.8. Enlarged region of spectrum
illustrating formation of compound E-S intermediate.
Enzyme concentration ~700µM, oxidant concentration 5mM,
buffer concentration 250mM. Time frame from 0s(red) to 10s,
reaction temperature held constant at 15°C.
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Figure 14: UV-Vis spectrum of BM3-F87G reacted with
peracetic acid at pH 6.8. Enlarged region of spectrum
illustrating formation of compound E-S intermediate.
Enzyme concentration ~800µM, oxidant concentration 5mM,
buffer concentration 250mM. Time frame from 0s(red) to 1s,
reaction temperature held constant at 15°C.
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Figure 15: UV-Vis spectrum of BMH-F87G reacted with m-CPBA
at pH 6.8. Enlarged region of spectrum illustrates
formation of compound E-S intermediate. Enzyme
concentration ~600µM, oxidant concentration 125µM, buffer
concentration 250mM. Time frame from 0s(red) to 1s,
reaction temperature held constant at 15°C.
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Figure 16: UV-Vis spectrum of BMH-F87G reacted with sodium
m-periodate at pH 6.8. Enlarged region of spectrum
illustrates formation of compound E-S intermediate. Enzyme
concentration ~700µM, oxidant concentration 125µM, buffer
concentration 250mM. Time frame from 0s(red) to 10s,
reaction temperature held constant at 15°C.
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Figure 17: UV-Vis spectrum of BMH-F87G reacted with
peracetic acid at pH 6.8. Enlarged region of spectrum
illustrates formation of compound E-S intermediate. Enzyme
concentration ~700µM, oxidant concentration 5mM, buffer
concentration 250mM. Time frame from 0s(red) to 1s,
reaction temperature held constant at 15°C.
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Figure 18: Deep View representation of distance between
outlying tyrosine residues of P450BM3. All other outlying
tyrosine residues greater than 10Ǻ in distance.
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Scheme I: Overall reaction of tyrosine dimer complex
formation from outlying, neighboring tyrosine residues of
P450BM3 when reacted with sodium m-periodate.
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Scheme II: Proposed reaction mechanism for the formation
of dimer complex between outlying tyrosine residues of
P450BM3 and P450BMH.
45
Fe
3+
O
+ HH
Fe
4+
O
Fe
4+
O
mcpba, iodosobenzene
peracetic acid, m-periodate
NH
Trp96
NH
Trp96
NADPH
.
+
.
+
370nm406nm
418nm
Cpd ICpd E-S
Scheme III: Formation of compound I and compound E-S
intermediates from reaction of P450BM3-F87G with alternate
oxidants.
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EPR analysis
Several EPR spectra with varying concentrations of m-
CPBA and iodosobenzene were recorded at pH 6.8 reacting
with P450BM3-F87G over a time course of ~5s; reaction time
varied between +/- 2s as a result of sample freezing time.
By increasing the oxidant concentration a more prominent
signal was produced in the g = 2 region of the spectra
which corresponded to an amino acid radical. This signal
coincided with a decrease in low spin ferric heme signal
which registered at g = 1.92, 2.25 and 2.41. The region
around g = 2 was analyzed at microwave powers ranging from
5 µW to 20 mW for reactions with both mCPBA and with
iodosobenzene. The spectrum obtained from the reaction
with mCPBA appeared to show two different radical species,
one at g = 2.005 with an isotropic line shape, and the
other a multiple-lined signal represented by distinct
components at g = 2.006, 2.017 and 2.026. The microwave
power saturation behavior of the two signals differed
noticeably, with the features at g = 2.006, 2.017 and g =
2.026 more easily saturated. The spectrum obtained from
the reaction with iodosobenzene showed similar signals, but
they were much more easily distinguished by varying the
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microwave power. The signal at g = 2.005 was very
difficult to saturate at high powers, while the multiple
lined signal was the dominant feature at low power. At 5
µW power, the latter signal comprised three features (g =
2.026, 2.017, 2.006) separated by 14-14.5 gauss, suggestive
of an amino acid radical. Additional preliminary EPR data
were acquired using 165 µM BM3-F87G and 1.7 mM mCPBA. With
this high mCPBA:P450 ratio, a broad low intensity feature
in the EPR spectrum at g= 1.78 emerged along with a sharp g
= 2 peak, and the ferric P450 signals at g = 2.41, 2.25 and
1.92 were weak.
Stopped-flow data suggested that the ES-like
intermediate in P450BM3 was considerably more stable than
it was in P450CAM. This could be due to the neighboring
tryptophan residue in the active site region of P450BM3
and, as a result, this compound ES-like intermediate could
be trapped without the need for a rapid-quench system. The
saturation behavior of the radical signal and the observed
hyperfine splitting at low power were consistent with the
presence of a protein radical; however, different
components of the EPR signal responded differently to
changes in the microwave power, indicating the likely
presence of multiple radical species. This became more
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apparent when iodosobenzene was used as an oxidant and the
EPR spectrum was recorded. The three signals observed in
the m-CPBA reaction were all present, but their relative
abundance was very different. The main species present in
the iodosobenzene reaction was characterized by a
multicomponent EPR signal with g-values listed previously
of 2.026, 2.017 and 2.006. Although these peaks were also
present in the mCPBA reaction, they were minor compared to
the main peak at g = 2.005. While we are unable to assign
the observed radical to a specific amino acid residue in
this intermediate, the behavior of the radical signal is
consistent with either a tyrosine or a tryptophan, or
possibly a combination of both.25 A possible explanation
for this is that the two radical species originate on
different amino acid side chains, and that the two oxidants
react differentially with these residues. Assuming that at
least one of the two surface tyrosine residues discussed
earlier may be oxidized, this is a definite possibility.
However, it is possible that the two oxidants produce
different ratios of the intermediates represented in Scheme
II. For example, the g = 2.005 signal that dominates the
mCPBA reaction may represent a small amount of compound I
(porphyrin π-cation radical), whereas the multicomponent
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signal dominating the iodosobenzene spectrum would
represent a protein radical, possibly Trp96. Rutter
reported the 9.5 GHz EPR spectrum for compound I of
chloroperoxidase (CPO) under several different conditions,
and in each case the signal consisted of g ~ 2 and g = 1.73
components.26 As with CPO, the preliminary EPR spectrum of
BM3-F87G, when mixed with mCPBA for ~ 1 s, using a 10:1
mCPBA:BM3 ratio, contained a sharp g ~ 2 component and a
broad weak signal at g = 1.78 (data not shown). The
experiment with BM3 was carried out at 10K using 20 mW
power, in contrast to the CPO experiment, where the
microwave power was between 50 µW and 1 mW, and the
temperature was between 3.6K and 30K. Although the
similarity of the CPO and BM3-F87G EPR spectra alone does
not prove that compound I is present in the P450
experiments, the combination of the EPR and the stopped-
flow data argue more strongly that a compound I-like
intermediate and a compound ES-like intermediate both are
produced using mCPBA as an oxidant, whereas with
iodosobenzene, the compound ES-like intermediate is
generated almost exclusively.
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Figure 19: EPR spectra of P450BM3-F87G reacted with high
concentrations of m-CPBA and iodosobenzene. Reaction time
with oxidant before freeze quenching in liquid N2 was ~5s.
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